fbpx Drug Discovery QuickFire Challenge | JLABS
Artificial Intelligence for Drug Discovery QuickFire Challenge
JLABS - Artificial Intelligence for Drug Discovery QuickFire Challenge

Artificial Intelligence for Drug Discovery QuickFire Challenge

Challenge ended

Up to $100,000 USD*





A2A Pharmaceuticals: At A2A Pharmaceuticals, our mission is to leverage proprietary computational systems including A.I., to accelerate development of novel drug alternatives for life threatening diseases like cancer, bacterial infections and muscular dystrophy.  



Envisagenics: Cloud-based drug-target discovery platform (SpliceCore) using AI to predict disease-causing aberrant splicing through the analysis of massive amounts of RNA-seq data. 



Tracery Ophthalmics: Tracery is a clinical stage ocular imaging and health tech company focused on Age Relate Macular Degeneration and blinding eye disease.  

The Challenge

Image paragraph

At Johnson & Johnson Innovation and Janssen Research & Development our goal is to improve the health and wellness of people around the world. Artificial intelligence (AI) poses unlimited opportunity for us to make a transformative impact on patients. Whether it be through new drug combinations, improved medical diagnostics, better accuracy in personalized medicine, or many other benefits - AI could save scientists valuable research time and bring new treatments to patients more quickly. To that end, Johnson & Johnson Innovation is looking to award up to $100,000 in grants, one year of JLABS residency & mentorship to the individuals or teams who submit the best ideas, technologies, or solutions that are using artificial intelligence to advance healthcare.

Rewards and benefits

  • *Up to $100,000 USD in grants for multiple winners
  • Residency at an available JLABS location
  • Mentoring & coaching from J&J experts

QuickFire Challenge innovation focus areas

We are looking for entrepreneurs & innovators with the best ideas, technologies, or solutions across all stages (ideation, pre-clinical, clinical, post-approval) that are using artificial intelligence to advance drug discovery & development in any of these areas:

  • Oncology & Immuno-oncology
  • Immunology
  • Cardiovascular & Metabolism
  • Infectious Diseases & Vaccines
  • Neuroscience
  • Pulmonary Hypertension
  • Rare Diseases
  • Pre-clinical safety studies
  • Systems pharmacology
  • Clinical trials
  • Precision Medicine
  • Chemo-informatics
  • In silico compound & safety profiling
  • Real world evidence


Applications Open
Submission Deadline
Judging Commences
Finalists Pitch at JLABS @ Toronto and Winners are Announced 

Application process

A panel of reviewers and judges will evaluate submissions based  on their ability to meet the following criteria:

  • Scientific/Technical Excellence
  • Novelty
  • Feasibility/Practicality
  • Perceived commercialization potential
  • Clarity on milestones and deliverables
  • Quality of Team and Resources
  • Plan for use of funds

Deadline to apply is October 27th, 2017
Winner(s) will be announced in December

About the Janssen Pharmaceutical Companies

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at Twitter.com/JanssenGlobal.


About Johnson & Johnson Innovation

Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JLINX, Johnson & Johnson Innovation – JJDC and our Business Development teams to create customized deals and novel 4 collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

Image paragraph
Image paragraph